InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.057 0.002 (3.64%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$84 Fourth U.S. Patent Secured for Efti and PD-1 Combination 14 Jul 2026 12:11PM $0.055 $0.057 risen by 3.64%
$84 TACTI-004 Update & Positive Mature Data from INSIGHT-003 13 Jul 2026 9:38AM $0.051 $0.057 risen by 11.76%
$84 Ceasing to be a substantial holder 1 Jul 2026 8:14AM $0.053 $0.057 risen by 7.55%
$84 Becoming a substantial holder 17 Jun 2026 8:22AM $0.046 $0.057 risen by 23.91%
$84 Ceasing to be a substantial holder 16 Jun 2026 8:16AM $0.048 $0.057 risen by 18.75%
$84 Becoming a substantial holder 15 Jun 2026 8:19AM $0.047 $0.057 risen by 21.28%
$84 Ceasing to be a substantial holder 10 Jun 2026 8:19AM $0.047 $0.057 risen by 21.28%
$84 Ceasing to be a substantial holder 9 Jun 2026 5:58PM $0.047 $0.057 risen by 21.28%
$84 Change in substantial holding 9 Jun 2026 8:13AM $0.048 $0.057 risen by 18.75%
$84 Becoming a substantial holder 9 Jun 2026 8:12AM $0.048 $0.057 risen by 18.75%
$84 Change in substantial holding 4 Jun 2026 5:30PM $0.050 $0.057 risen by 14%
$84 Immutep Presents Positive IMP761 Phase I Data at EULAR 2026 4 Jun 2026 8:23AM $0.051 $0.057 risen by 11.76%
$84 Change in substantial holding 29 May 2026 5:03PM $0.053 $0.057 risen by 7.55%
$84 Efti immune activation associated with improved survival 28 May 2026 9:18AM $0.054 $0.057 risen by 5.56%
$84 Change in substantial holding 27 May 2026 6:51PM $0.054 $0.057 risen by 5.56%
$84 Ceasing to be a substantial holder 11 May 2026 8:16AM $0.060 $0.057 fallen by 5%
$84 Immutep Receives Nasdaq Notice of Bid Price Deficiency 30 Apr 2026 9:21AM $0.063 $0.057 fallen by 9.52%
$84 Immutep Quarterly Activities Report and Appendix 4C 30 Apr 2026 9:01AM $0.063 $0.057 fallen by 9.52%
$84 Change in substantial holding 27 Apr 2026 8:15AM $0.070 $0.057 fallen by 18.57%
$84 Change in substantial holding 27 Apr 2026 8:13AM $0.070 $0.057 fallen by 18.57%
$84 Change in substantial holding 23 Apr 2026 8:15AM $0.074 $0.057 fallen by 22.97%
$84 Abstract on Efti accepted for presentation at ASCO 2026 22 Apr 2026 10:05AM $0.073 $0.057 fallen by 21.92%
$84 Change in substantial holding 17 Apr 2026 8:22AM $0.075 $0.057 fallen by 24%
$84 Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma 15 Apr 2026 9:27AM $0.039 $0.057 risen by 46.15%
$84 Change in substantial holding 13 Apr 2026 8:17AM $0.040 $0.057 risen by 42.50%

1 - 25 of 773 results

Page 1 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.